CDER “Comprehensive” Reorganization To Follow After CBER-CDER Merger

CDER plans to reorganize under indication-based divisions following the merger between the center for drugs and center for biologics, Office of New Drugs Director John Jenkins, MD, said during the Biotechnology Industry annual meeting in Washington, D.C. June 24